Literature DB >> 10325537

Demography, symptomatology, and course of disease in ambulatory zoster patients. A physician-based survey in Germany.

W Meister1, A Neiss, G Gross, H Doerr, W Höbel, J Malin, J von Essen, B Reimann, C Witke, P Wutzler.   

Abstract

This survey summarises the observations of physicians who prospectively recorded clinically relevant data on their patients with an episode of herpes zoster. These included demography of patients, signs and symptoms during the prodromal phase, relevant history, description of disease at the first visit, therapeutic measures and description of disease, and occurrence of postherpetic neuralgia (pain 4-5 weeks after crusting) at the second visit. A total of 2,063 patients were reported to the data management centre. The age distribution resembles that reported in the literature including the notable increase in zoster frequency with advancing age. Almost 20% of the patients, however, were 30 years old or less, and this contrasts markedly with the published literature. Age modifies the frequency of the dermatome afflicted: more cranial and less thoracic manifestations were observed with increasing age. Almost all patients reported symptoms which may be attributed to a prodromal phase, especially pain in the affected dermatome (82%). The incidence of postherpetic neuralgia was 28%. A complicated disease course such as visceral, ocular, or otological involvement, or progression to additional dermatomes was seen in almost 10% of the patients.

Entities:  

Mesh:

Year:  1998        PMID: 10325537     DOI: 10.1159/000024949

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  14 in total

1.  [Frequent pathogen-induced diseases of the scalp].

Authors:  D Abeck
Journal:  Hautarzt       Date:  2014-12       Impact factor: 0.751

Review 2.  [Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics].

Authors:  Miriam Wittek; Hans Wilhelm Doerr; Regina Allwinn
Journal:  Med Klin (Munich)       Date:  2010-05-26

3.  [Diagnostics and management of herpes zoster ophthalmicus].

Authors:  R N Werner; N-I Steinhorst; A Nast; U Pleyer
Journal:  Ophthalmologe       Date:  2017-10       Impact factor: 1.059

4.  Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.

Authors:  Ralph P Insinga; Robbin F Itzler; James M Pellissier
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 5.  [Epidemiology of chronic non-malignant pain in Germany].

Authors:  R Wolff; C Clar; C Lerch; J Kleijnen
Journal:  Schmerz       Date:  2011-02       Impact factor: 1.107

Review 6.  Reducing the burden of Herpes Zoster in Italy.

Authors:  Giovanni Gabutti; Elisabetta Franco; Paolo Bonanni; Michele Conversano; Antonio Ferro; Marzia Lazzari; Stefania Maggi; Alessandro Rossi; Silvestro Scotti; Francesco Vitale; Antonio Volpi; Donato Greco
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

7.  The consistency of shingles and its significance for health monitoring.

Authors:  Douglas M Fleming; Aad Bartelds; Rachel S Chapman; Kenneth W Cross
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 12.434

8.  A prognostic score for postherpetic neuralgia in ambulatory patients.

Authors:  W Meister; A Neiss; G Gross; H W Doerr; W Höbel; J P Malin; J von Essen; B Y Reimann; C Witke; P Wutzler
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 7.455

9.  Burden of herpes zoster-associated chronic pain in Italian patients aged 50 years and over (2009-2010): a GP-based prospective cohort study.

Authors:  Hélène Bricout; Emilia Perinetti; Paolo Marchettini; Pietro Ragni; Carla Maria Zotti; Giovanni Gabutti; Antonio Volpi; Elisabetta Franco
Journal:  BMC Infect Dis       Date:  2014-12-06       Impact factor: 3.090

Review 10.  Similar herpes zoster incidence across Europe: results from a systematic literature review.

Authors:  Sybil Pinchinat; Ana M Cebrián-Cuenca; Hélène Bricout; Robert W Johnson
Journal:  BMC Infect Dis       Date:  2013-04-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.